US EditionHeidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business – Optimum Strategic CommunicationsLink to: Have we reached “peak drugs pricing”?Scroll to top
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business – Optimum Strategic CommunicationsLink to: Have we reached “peak drugs pricing”?Scroll to top
Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started First patient in clinical study dosed with the second ATAC candidate HDP-102 in the non-Hodgkin lymphoma (NHL) indication Amendment of contract with HealthCare Royalty; payment of […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
